288 related articles for article (PubMed ID: 16941347)
1. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
3. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
[TBL] [Abstract][Full Text] [Related]
4. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
[TBL] [Abstract][Full Text] [Related]
5. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
8. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice.
Ivanov AP; Dragunsky EM; Chumakov KM
J Infect Dis; 2006 Feb; 193(4):598-600. PubMed ID: 16425140
[TBL] [Abstract][Full Text] [Related]
9. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
10. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
11. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
12. Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.
Taffs RE; Chernokhvostova YV; Dragunsky EM; Nomura T; Hioki K; Beuvery EC; Fitzgerald EA; Levenbook IS; Asher DM
J Infect Dis; 1997 Feb; 175(2):441-4. PubMed ID: 9203668
[TBL] [Abstract][Full Text] [Related]
13. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
[TBL] [Abstract][Full Text] [Related]
14. Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan.
Satoh H; Tanaka-Taya K; Shimizu H; Goto A; Tanaka S; Nakano T; Hotta C; Okazaki T; Itamochi M; Ito M; Okamoto-Nakagawa R; Yamashita Y; Arai S; Okuno H; Morino S; Oishi K
Vaccine; 2019 Mar; 37(14):1964-1971. PubMed ID: 30827736
[TBL] [Abstract][Full Text] [Related]
15. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
17. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
18. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains.
Martín J; Crossland G; Wood DJ; Minor PD
J Gen Virol; 2003 Jul; 84(Pt 7):1781-1788. PubMed ID: 12810872
[TBL] [Abstract][Full Text] [Related]
19. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
Hu Y; Wang J; Zeng G; Chu K; Jiang D; Zhu F; Ying Z; Chen L; Li C; Zhu F; Yin W
J Infect Dis; 2019 Oct; 220(10):1551-1557. PubMed ID: 30958543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
